CG Oncology Investor Relations Material
Latest events
Study Result
CG Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CG Oncology Inc
Access all reports
CG Oncology Inc. is a late-stage clinical biopharmaceutical company primarily engaged in the development and commercialization of innovative treatments for bladder cancer. The company's main focus is on creating a bladder-sparing therapeutic option for patients suffering from this disease. CG Oncology's leading product candidate, cretostimogene, is currently in clinical development targeting high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients who have not responded to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care. The company is headquartered in Irving, California, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
CGON
Country
🇺🇸 United States